Conditions: Healthy Volunteers
Keywords: Rotigotine Neupro® Transdermal Patch
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 50
Healthy volunteers: yes

Brief summary:
The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of two Rotigotine patches of two different formulations

Detailed description:

Arms:
arm 1: Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days arm 2: Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days

Interventions: intervention 1: Rotigotine transdermal patch
Intervention descriptions: intervention 1: Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours

Protocol document: